Biogen Idec Earnings: Here’s Why Investors are Bidding Up Shares
January 28, 2013
Biogen Idec Inc. (NASDAQ:BIIB) delivered a profit and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 1.1%.
Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!
Biogen Idec Inc. Earnings Cheat Sheet
Results: Net income decreased -2.71% to $292.1 million ($1.4 per diluted share) in the quarter versus a net gain of $300.24 million in the year-earlier quarter.
Revenue: Rose 7.03% to $1.42 billion from the year-earlier quarter.
Actual vs. Wall St. Expectations: Biogen Idec Inc. reported adjusted net income of $1.4 per share. By that measure, the company missed the mean analyst estimate of $1.46. It beat the average revenue estimate of $1.39 billion.
Premium Newsletters
Gold & Silver
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
Learn More
Commodities Premium
There's always a bull market in some sector! Find the best opportunities in commodities.
Learn more
ETF Investing
At last, a trading system that buys the right ETFs at the right time, time after time!
Learn more
Wall St. Cheat Sheet has been featured in these fine media outlets:
